| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.021 | 0.8 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.8 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.015 | 0.8 |